Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site Oct 19, 2026 06:45AM
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model Oct 8, 2026 06:45AM
Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204 Oct 6, 2026 06:45AM
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update Oct 6, 2026 06:45AM
Marvel Biosciences closes private placement raising $1.6 million Sep 29, 2026 05:53PM


Sep 29, 2026 05:52PM Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million
Aug 5, 2026 05:00AM Marvel Biosciences reports MB-204 preclinical results in Fragile X model
Aug 5, 2026 05:00AM Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
Jun 26, 2026 07:00AM New Autism Research to be Presented at European Purine Scientific Meeting
Jun 8, 2026 07:00AM Marvel Biosciences receives Australian patent allowance for MB-204
Jun 8, 2026 07:00AM Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
Apr 23, 2026 07:30AM Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
Apr 16, 2026 07:00AM Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
Apr 7, 2026 12:26PM Marvel Biosciences secures funding for autism drug trial from 5 Horizons
Apr 7, 2026 07:30AM Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
Mar 30, 2026 07:30AM Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
Mar 25, 2026 07:30AM Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
Mar 18, 2026 07:02AM Marvel Biosciences receives US patent for autism drug candidate MB-204
Mar 18, 2026 07:00AM Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204